Stockreport

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF If approved, AstraZeneca and Daiichi Sankyo's ENHERTU has the potential to become a new standard of care in this early breast cancer setting WILMINGTON, Del., March 0 [Read more]